Ruijia Yang

Ruijia Yang

Auto-generated profile, based on publicly available information

Ruijia Yang

Department of Biochemistry, Basic Medical College, Shanxi Medical University, Taiyuan, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
CCChongwei Chen
Chongwei Chen
SZSujing Zong
Sujing Zong
ZWZhenyu Wang
Zhenyu Wang
RYRuijia Yang
Ruijia Yang
YGYanjing Guo
Yanjing Guo
SWShaowei Wang
Shaowei Wang
Osteoclast (OC) abnormalities lead to many osteolytic diseases, such as osteoporosis, inflammatory bone erosion, and tumor-induced osteolysis. Exploring effective strategies to remediate OCs dysregulation is essential. FTY720, also known as fingolimod, has been approved for the treatment of multiple sclerosis and has anti-inflammatory and immunosuppressive effects. Here, we found that FTY720 inhibited osteoclastogenesis and OC function by inhibiting nuclear factor kappa-B (NF-κB) signaling. Interestingly, we also found that FTY720 inhibited osteoclastogenesis by upregulating histone deacetylase 4 (HDAC4) expression levels and downregulating activating transcription factor 4 (ATF4) expression levels. In vivo, FTY720 treatment prevented lipopolysaccharide- (LPS-) induced calvarial osteolysis and significantly reduced the number of tartrate-resistant acid phosphatase- (TRAP-) positive OCs. Taken together, these results demonstrate that FTY720 can inhibit osteoclastogenesis and ameliorate inflammation-induced bone loss. Which may provide evidence of a new therapeutic target for skeletal diseases caused by OC abnormalities.

1 January 2021
Verified
Conference Paper
Open access
JXJia Xu
Jia Xu
RYRuijia Yang
Ruijia Yang
CXChaoran Xia
Chaoran Xia
ZYZhixiang Yan
Zhixiang Yan
PLPeng Luo
Peng Luo
HWHuiling Wang
Huiling Wang